Here are the latest stories being discussed in biopharma today:

In recent healthcare market news:

1. UnitedHealth Group’s CEO, Andrew Witty, was questioned by Senators over the company’s handling of a cyberattack that saw them paying a $22 million ransom. The key question of the inquiry was whether UnitedHealth is too large, with concerns raised about the company’s monopoly-like status, particularly following this major security breach.

2. In a first-quarter update, Pfizer indicated that cost-cutting measures are ‘largely complete’, setting a ‘cautiously optimistic’ tone for the future. The company has reigned in some of its bolder promises from recent years, and has said any significant bolt-on M&A activity is not expected in the near future.

3. Boehringer Ingelheim has identified Humira, a drug from AbbVie, as a key rival for their Humira biosimilar Cyltezo. This follows recent FDA approval of Cyltezo, and an announcement from the company that they aim to push Humira off of PBM formularies for their biosimilar to gain more market share.

4. Following a ruling against them in a lawsuit concerning the Inflation Reduction Act, Johnson & Johnson (J&J) and Bristol Myers Squibb have filed appeals. This comes as several pharma companies race to halt Medicare price negotiations set to go into effect in 2026.

5. Senator Maggie Hassan (D-NH) has accused GlaxoSmithKline (GSK) of going back on its commitment to cap inhaler prices at $35 per month. This follows GSK’s discontinuation of a branded version of a pediatric inhaler in favor of an authorized generic version, which is not subject to the same price cap.

6. J&J has proposed a $6.5 billion settlement plan for the tens of thousands of lawsuits related to its talc products. Having fallen into controversy over allegations that its talc products caused cancer, J&J hopes to appeal to claimants to support the plan before filing for Chapter 11.

Read on for more stories from the healthcare market.